AYTU BIOPHARMA, INC Contract Liability (Deferred Revenue)
AYTU BIOPHARMA, INC (AYTU) had Contract Liability (Deferred Revenue) of $100.00 thousand as of 2022-12-31, per its 10-Q filed 2023-02-21.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-02-21
- 2022-12-31: Contract with Customer, Liability, Current $100.00K.
- 2022-09-30: Contract with Customer, Liability, Current $100.00K.
- 2022-06-30: Contract with Customer, Liability, Current $400.00K.
- 2022-03-31: Contract with Customer, Liability, Current $100.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2022-12-31 | $100.00K 10-Q · filed 2023-02-21 |
| 2022-09-30 | $100.00K 10-Q/A · filed 2023-02-21 |
| 2022-06-30 | $400.00K 10-Q/A · filed 2023-02-21 |
| 2022-03-31 | $100.00K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $200.00K 10-Q · filed 2022-02-14 |
| 2021-09-30 | $200.00K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $200.00K 10-Q · filed 2022-05-16 |
| 2020-12-31 | $475.68K 10-Q · filed 2021-02-11 |
| 2020-09-30 | $232.58K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $339.34K 10-Q · filed 2021-02-11 |
| 2019-06-30 | $0.00 10-K · filed 2020-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |